Validates BIOLASE
REPAIR® Perio Protocol is a Superior
Alternative as it pertains to patient reported
outcomes.
LAKE
FOREST, Calif., Nov. 8, 2023
/PRNewswire/ -- BIOLASE, Inc.(NASDAQ: BIOL), the global leader in
dental lasers, today announced groundbreaking findings from a
12-month follow-up to a clinical trial performed at The McGuire
Institute™. The findings will be published in the November 2023 issue of the Journal of
Periodontology. The pioneering study was designed to meet the
stringent American Association of Periodontology Best Evidence
Consensus (BEC) standards, and is the first-of-its-kind study to
compare BIOLASE's REPAIR® Perio protocol to the
traditional minimally invasive surgical technique (MIST) treatment
of moderate to severe generalized periodontitis.
Key highlights include:
- Clinically Proven and Validated by Scientific Research
The study confirms that BIOLASE's Waterlase REPAIR®
Perio protocol has similar and sustainable clinical outcomes as
compared to traditional MIST in treating intrabony defects over the
12-month study thus reaffirming rigorous scientific research and
the laser's clinical efficacy.
- Enhanced Positive Patient Experience
Patients who underwent BIOLASE's Waterlase REPAIR® Perio
laser treatment reported significantly better patient-reported
outcomes (PROs) at six months. These findings show that patients
experienced less pain, reduced bleeding, and minimal discomfort,
indicating a patient-friendly approach to periodontal care.
- Safety and Minimal Invasiveness
The study found no adverse events associated with BIOLASE's
Waterlase REPAIR® Perio laser procedure, highlighting
its safety. Furthermore, it emphasizes that this laser treatment is
minimally invasive, ensuring a highly effective and more
comfortable experience for patients.
- Faster Recovery
Patients in the BIOLASE Waterlase group reported a quicker
reduction in swelling and discomfort, suggesting a faster and more
comfortable recovery compared to traditional treatment.
"This exciting study provides further strong evidence that our
Waterlase laser and REPAIR® Perio protocol is a safe and
effective alternative to surgical treatment for intrabony
periodontal defects with lasting results," said Dr. Russell Morrow, the Chief Dental Officer at
BIOLASE. "The results ensure patients will not have to compromise
on effectiveness, or comfort when choosing a less invasive
approach."
BIOLASE's Waterlase laser is a minimally invasive laser that can
be used to treat a variety of dental conditions, including
intrabony periodontal defects. Intrabony periodontal defects are
pockets that form between the tooth and bone and can lead to tooth
loss. The Waterlase laser works by vaporizing the diseased tissue
and stimulating the body to produce new bone and gum tissue.
"The study provides a firm rationale for an alternative surgical
approach in the treatment of intrabony periodontal defects and
forges the path for future comparisons using regenerative therapies
in conjunction with the REPAIR® Perio technique," said
Rick H. Heard, DDS, MS and Executive
Director of Clinical Research and Operations of the McGuire
Institute, a network of master clinicians trained and qualified to
conduct high level clinical research in a practice based setting
and located strategically throughout the
United States. "It also supports superiority over a
minimally invasive surgical technique with respect to patient
reported outcomes."
Additionally, the McGuire study has earned a well-deserved
nomination for the 2024 DrBicuspid Dental Excellence Awards,
affectionately known as the "Cuspies," a platform to honor the best
in dental innovation and excellence. Among the esteemed categories,
the "Dental Study of the Year" spotlights research that promises to
reshape the future of dental practice.
Winning this prestigious award at the Cuspies would not only be
an accolade, but a testament to how the McGuire study could
potentially redefine and elevate the standard of care for
periodontal patients globally. It is an opportunity to celebrate a
study with the power to reshape the landscape of periodontal
treatment, setting new benchmarks for excellence in the dental
field.
About BIOLASE
BIOLASE is a medical device company that develops, manufactures,
markets, and sells laser systems in dentistry and medicine.
BIOLASE's products advance the practice of dentistry and medicine
for patients and healthcare professionals. As of December 31, 2022, BIOLASE's proprietary laser
products incorporate approximately 259 patented and 24
patent-pending technologies designed to provide biologically and
clinically superior performance with less pain and faster recovery
times. BIOLASE's innovative products provide cutting-edge
technology at competitive prices to deliver superior results for
dentists and patients. BIOLASE's principal products are dental
laser systems that perform a broad range of dental procedures,
including cosmetic and complex surgical applications. From 1998
through December 31, 2022, BIOLASE
has sold over 45,500 laser systems in over 80 countries around the
world. Laser products under development address BIOLASE's core
dental market and other adjacent medical and consumer
applications.
For updates and information on Waterlase iPlus®,
Waterlase Express™, and laser dentistry, find BIOLASE online at
www.biolase.com, Facebook at www.facebook.com/biolase, Twitter
at www.twitter.com/biolaseinc, Instagram at
www.instagram.com/waterlase_laserdentistry, and LinkedIn at
www.linkedin.com/company/biolase.
BIOLASE®, Waterlase® and Waterlase iPlus® are registered
trademarks of BIOLASE, Inc.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains forward-looking statements, as that
term is defined in the Private Litigation Reform Act of 1995, that
involve significant risks and uncertainties, including statements,
regarding BIOLASE's expected revenue and revenue growth and beliefs
regarding its financial resources. Forward-looking statements can
be identified through the use of words such as "may," "might,"
"will," "intend," "should," "could," "can," "would," "continue,"
"expect," "believe," "anticipate," "estimate," "predict,"
"outlook," "potential," "plan," "seek," and similar expressions and
variations or the negatives of these terms or other comparable
terminology. Readers are cautioned not to place undue reliance on
these forward-looking statements, which reflect BIOLASE's current
expectations and speak only as of the date of this release. Actual
results may differ materially from BIOLASE's current expectations
depending upon a number of factors. These factors include, among
others, the coronavirus (COVID-19) and the effects of the outbreak
and actions taken in connection therewith, adverse changes in
general economic and market conditions, competitive factors
including but not limited to pricing pressures and new product
introductions, uncertainty of customer acceptance of new product
offerings and market changes, risks associated with managing the
growth of the business, and those other risks and uncertainties
that are described in the "Risk Factors" section of BIOLASE's most
recent annual report filed on Form 10-K filed with the Securities
and Exchange Commission. Except as required by law, BIOLASE does
not undertake any responsibility to revise or update any
forward-looking statements.
For further information, please contact:
EVC Group LLC
Michael Polyviou / Todd Kehrli
(732) 933-2754
mpolyviou@evcgroup.com / tkehrli@evcgroup.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/landmark-study-performed-by-the-independent-mcguire-institute-confirms-positive-12-month-clinical-outcomes-for-biolase-repair-perio-protocol-301981095.html
SOURCE BIOLASE, Inc.
